Clinical

Unmet needs include both improved myasthenia gravis treatments as well as a way to monitor progression of the disease, said James F. Howard, Jr, MD, professor of neurology at the University of North Carolina at Chapel Hill.

The approval makes the drug Europe’s first and only interleukin (IL)-17A inhibitor approved for the condition.

Physicians should proactively ask patients what alternative therapies, if any, they are using.

The 2023 European Hematology Association (EHA) Congress, convening virtually and in Frankfurt, Germany, from June 8-11, 2023, will feature cutting-edge findings in oncology and hematology, with a special focus on incorporating patient-reported outcomes and real-world data.

Key opinion leaders provide insight on the effect of racial disparities on patients with cervical and breast cancer.

Experts expand on racial and social factors influencing maternal mortality.

Using propensity score matching in a US nationally representative sample, authors found the effect of nonadherence to diabetes guidelines on health care expenditures of patients with diabetes.

Ixazomib was first approved in the United States in 2015 for relapsed/refractory multiple myeloma.

Payor considerations in the treatment of HIV are explored.

A panel of experts open a discussion surrounding the current disease landscape of HIV.

In their closing thoughts, the panelists discuss financial considerations for treating patients with RRMM.

Building strong support systems from both clinical and personal perspectives can drive optimal patient outcomes.

Barriers to sufficient multiple myeloma treatment are explored.

In some cases, individuals of Puerto Rican descent face lower risk than other Hispanic groups in the United States.

Financial impacts associated with respiratory syncytial virus infection are highlighted.

Dr Welch leads a conversation regarding strategies to increase awareness of respiratory syncytial virus.

Wanda Filer, MD, MBA, FAAFP, discusses the prevalence of RSV.

Expert panelists discuss bridging communication between payers and providers in the AD treatment pathway.

White-glove service provided by local pharmacies can increase convenience for patients navigating atopic dermatitis (AD) treatment options.

Insurance is by far the most important factor of whether patients followed up with treatment after getting screened for glaucoma, said Byron L. Lam, MD, professor of ophthalmology, University of Miami Miller School of Medicine's Bascom Palmer Eye Institute.

To stratify the risk of future epilepsy, physicians have historically used lumbar puncture, neuroimaging, and electroencephalography in these patients.

Lexicon Pharmaceuticals received approval for sotagliflozin to treat a broad range of left ventricular ejection fraction, for patients with and without diabetes.

Christopher P. Cannon, MD, a professor of medicine at Harvard Medical School and senior physician in the Cardiovascular Division at Brigham and Women’s Hospital, spoke about the benefit seen in a study of sotagliflozin for patients with acute heart failure.

The predictive ability of cough sound algorithms shows promise in detecting acute respiratory diseases, study finds.

Current myasthenia gravis therapies can exacerbate comorbidities or create other complications, said James F. Howard Jr, MD, professor of neurology at the University of North Carolina at Chapel Hill.

The LIBERTY-PN PRIME and PRIME2 trials investigated itch response to dupilumab among patients who have prurigo nodularis.

An investigation of management patterns after initial radiographic diagnosis of small renal masses showed that early urologist referral was associated with guideline-concordant care.

Sharon Deans, MD, MPH, MBA, and Roxie Cannon Wells, MD, discuss disparities affecting maternal mortality rates.

Ensuring appropriate pre-pregnancy through postnatal care is critical for optimal health of mother and child.

Investigators said longer-term outcomes from chimeric antigen receptor (CAR) T-cell therapies are still a significant question in patients who have non-Hodgkin lymphoma (NHL) or acute lymphoblastic leukemia (ALL).